Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Daniel Polhamus"'
Autor:
Ophelia Yin, Hamim Zahir, Jonathan French, Daniel Polhamus, Xiaoning Wang, Michiel van deSande, William D. Tap, Hans Gelderblom, Andrew J. Wagner, John H. Healey, Jonathan Greenberg, Dale Shuster, Silvia Stacchiotti
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 11, Pp 1422-1432 (2021)
Abstract This analysis was conducted to assess exposure–response relationships for efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor. Efficacy was assessed categorically by overall response rate (ORR) with Response
Externí odkaz:
https://doaj.org/article/e98d8752c9444f7c9cdac6701994c7d3
Autor:
Tommy Li, Daniel Polhamus, Craig Thalhauser, Apurvasena Parikh, Manish Gupta, Mariana Sacchi, Steven Xu
Publikováno v:
Cancer Research. 83:2798-2798
Background: Epcoritamab, a bispecific antibody, binds to CD3 on T cells and CD20 on B cells to induce T-cell-mediated killing of CD20+ malignant B cells. For T-cell engagers, CRS is a potential adverse event. Step-up dosing (SUD) is used to mitigate
Autor:
Dale Shuster, Hans Gelderblom, Hamim Zahir, Michiel A. J. van de Sande, William D. Tap, Daniel Polhamus, Jonathan French, John H. Healey, Silvia Stacchiotti, Ophelia Yin, Jonathan Greenberg, Xiaoning Wang, Andrew J. Wagner
Publikováno v:
CPT: Pharmacometrics and Systems Pharmacology, 10(11), 1422-1432. WILEY
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 11, Pp 1422-1432 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 11, Pp 1422-1432 (2021)
CPT: Pharmacometrics & Systems Pharmacology
This analysis was conducted to assess exposure–response relationships for efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor. Efficacy was assessed categorically by overall response rate (ORR) with Response Evaluatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fde6cee7310aa36880d826b65e2155e
https://hdl.handle.net/1887/3274139
https://hdl.handle.net/1887/3274139
Autor:
Shweta Vadhavkar, Xin Wang, Shang-Chiung Chen, Alexander Strasak, Silke Hoersch, Jonathan French, Daniel Polhamus, Jin Yan Jin, Chunze Li, Melanie Smitt, Matthew M. Riggs, Sandhya Girish, Angelica Quartino
Publikováno v:
British Journal of Clinical Pharmacology. 83:2767-2777
Aims We conducted population pharmacokinetic (PopPK) and exposure-response analyses for trastuzumab emtansine (T-DM1) to assess the need for T-DM1 dose optimization in patients with low exposure by using TH3RESA study data (NCT01419197). The randomiz
Autor:
Jonathan F. French, Sandhya Girish, Shweta Vadhavkar, Priya Agarwal, Dan Lu, Shang-Chiung Chen, Alexander Strasak, Chunze Li, Jin Yan Jin, Matthew M. Riggs, Angelica Quartino, Monika Patre, Daniel Polhamus
Publikováno v:
Cancer chemotherapy and pharmacology. 84(1)
The phase III MARIANNE study investigated single-agent trastuzumab emtansine (T-DM1) and combination T-DM1 plus pertuzumab as the first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). Pharma
Autor:
William J. Sandborn, Severine Vermeire, Krisztina Kisfalvi, Chunlin Chen, Geert R. D'Haens, Wenwen Zhang, Nathanael L. Dirks, Wan Sun, Maria Rosario, Daniel Polhamus, Brian G. Feagan
Publikováno v:
Gastroenterology. 158:S-458
Autor:
James A. Rogers, Richard L. Lalonde, Daniel Polhamus, Robert Hemmings, Lisa J. Bain, Klaus Romero, Vikram Sinha, Spiros Vamvakas, Diane Stephenson, Maria Isaac, Yaning Wang, Luca Pani, Ruolun Qiu, Kaori Ito, Brian Corrigan, David Brown, Richard C. Mohs
Publikováno v:
Clinical Pharmacology & Therapeutics. 97:210-214
Failures in trials for Alzheimer’s disease (AD) may be attributable to inadequate dosing, population selection, drug inefficacy, or insufficient design optimization. The Coalition Against Major Diseases (CAMD) was formed in 2008 to develop drug dev
Autor:
Daniel Polhamus, Klaus Romero, Diane Stephenson, James A. Rogers, William R. Gillespie, Marc R. Gastonguay, Ruolun Qiu, Kaori Ito, Brian Corrigan
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 39:479-498
Our objective was to develop a beta regression (BR) model to describe the longitudinal progression of the 11 item Alzheimer's disease (AD) assessment scale cognitive subscale (ADAS-cog) in AD patients in both natural history and randomized clinical t
Publikováno v:
Applied Pharmacometrics ISBN: 9781493913039
Alzheimer’s disease (AD) currently affects over 36 million people worldwide, without any approved disease-modifying products capable of slowing or arresting the disease, and prevalence expected to triple by 2050. Clinical trial failures attributabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ee060c5553ece7b7af2f558f9f4f68a
https://doi.org/10.1007/978-1-4939-1304-6_15
https://doi.org/10.1007/978-1-4939-1304-6_15
Publikováno v:
Alzheimer's & Dementia. 9